Life’s essential 8 and mortality in US adults with metabolic dysfunction-associated steatotic liver disease Authors: Yingying Zhang, Pingping Wang, Fan Tu, Hao Kang, Chengfeng Fu Published: 2024 ABSTRACT AbstractBackgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is linked to increased all-cause mortality due to metabolic dysfunctions like obesity, diabetes, and cardiovascular diseases. This study examines the association between Life’s Essential 8 (LE8) scores and both all-cause and cardiovascular disease (CVD) mortality in MASLD participants.MethodsData from 5,916 MASLD participants in the NHANES (2005–2018) were analyzed. Associations between LE8 scores and all-cause and CVD mortality were assessed using Cox proportional hazards models, with follow-up until December 31, 2019. Dose-response relationships and survival differences were evaluated using Kaplan-Meier survival curves and Restricted Cubic Spline models.ResultsOver a median follow-up of 7.6 years, moderate and high LE8 scores were associated with 33% (HR: 0.67; 95% CI: 0.56–0.79) and 47% (HR: 0.53; 95% CI: 0.33–0.84) lower risk of all-cause mortality, respectively, compared to low scores. For CVD mortality, the adjusted HRs were 0.56 (95% CI: 0.41–0.78) and 0.35 (95% CI: 0.12-1.0). Higher LE8 scores were significantly associated with reduced cumulative incidence of all-cause and CVD mortality (log-rank P < 0.001). A 10-point increase in health behavior scores, particularly in diet, physical activity, and nicotine exposure, was linked to an 11% reduction in all-cause mortality risk and an 11% reduction in CVD mortality risk. Among health factors, only blood glucose showed a significant association with CVD mortality.ConclusionHigher LE8 scores in MASLD patients are associated with lower mortality risk, suggesting the potential value of promoting cardiovascular health in this population. Further research is needed to confirm these associations.Graphical Abstract Supplementary InformationThe online version contains supplementary material available at 10.1186/s12889-024-20919-6.Keywords: MASLD, Life’s essential 8, All-cause mortality, CVD mortality, National health and nutrition examination survey Introduction After a global Delphi consensus, the term “steatotic liver disease” (SLD) was introduced to replace “fatty liver disease” and “metabolic dysfunction-associated steatotic liver disease” (MASLD) became the new term for “non-alcoholic fatty liver disease” (NAFLD) [1]. According to national data from 2000 to 2019, MASLD has the highest prevalence among 11 cardiometabolic diseases, including type 2 diabetes (T2DM) and ischemic heart disease (IHD) [2]. MASLD affects approximately 31.3% of the U.S. population, impacting all socioeconomic strata [3]. MASLD highlights the critical role of systemic metabolic dysfunction in liver disease and its close links to extrahepatic metabolic disorders such as obesity, diabetes, and cardiovascular disease (CVD) [4–6]. There is significant overlap in risk factors and pathophysiology among MASLD, metabolic syndrome, and atherosclerosis, which increases the risk of complications and mortality [7, 8]. The American Heart Association (AHA) established Life’s Simple 7 (LS7) in 2010 as a means to advocate for cardiovascular health (CVH). LS7 encompasses adherence to a nutritious diet, engagement in regular physical exercise, maintenance of a healthy body mass index, abstention from smoking, maintenance of optimal blood pressure levels, maintenance of normal fasting blood glucose levels, and maintenance of normal total cholesterol levels [9]. Nevertheless, LS7 has several limitations, such as the exclusion of sleep health and the utilization of a simplified cumulative scoring approach. These drawbacks decrease its ability to accurately measure individual variations and changes [10]. In order to tackle these problems, AHA presented an updated method for measuring CVH called Life’s Essential 8 (LE8), which quantifies the original metrics (LS7) along with the addition of sleep health [10]. Cardiometabolic risk factors are closely linked to all-cause mortality in MASLD, making the promotion of CVH a potentially effective strategy to reduce the MASLD burden [11]. However, The National Health and Nutrition Examination study (NHANES) data show controversial results regarding the association between metabolic-associated fatty liver disease (MAFLD) and long-term mortality. Some studies found that MAFLD is associated with increased all-cause mortality, while others, after adjusting for alcohol-related liver disease (ALD), found no significant association [12–15]. MASLD’s definition includes considerations for alcohol and viral infections, emphasizing metabolic and obesity factors [16]. Both MASLD and MAFLD show elevated all-cause mortality risks compared to NAFLD, suggesting that the increased mortality in MASLD is more likely due to metabolic factors rather than excessive alcohol consumption [14]. Therefore, research on adverse outcomes in MASLD populations is crucial. By analyzing the association between LE8 and mortality rates among MASLD individuals, we aim to uncover more insights into the management and prevention of MASLD, providing new perspectives for public health policies and clinical practices. Materials and methods Study design and population During seven interview cycles from NHANES 2005 to 2018, a total of 70,190 individuals were initially evaluated. After excluding those under 18 years old, additional exclusions were made for pregnant participants, those without LE8 data, individuals with the fatty liver index (FLI) < 60 or missing variables for its calculation, those with excessive alcohol intake, participants with other liver diseases, non-MASLD individuals, and those with missing follow-up or covariate data. Ultimately, 5,916 MASLD participants were included (Fig. 1). Flow diagram of the screening and enrollment of study participants Definitions of LE8 LE8, an enhancement of AHA’s LS7, includes four health behaviors (diet, physical activity [PA], nicotine exposure, sleep health) and four health factors (body mass index [BMI], blood lipids, blood glucose, blood pressure) [10, 17]. Nutritional intake is quantified using USDA’s automated multiple-pass method through 24-hour dietary recall interviews. PA includes self-reported weekly time spent on activities like walking, cycling, and leisure activities. Nicotine exposure is assessed via self-reported smoking or use of nicotine delivery systems, including passive exposure from cohabitation with active smokers. Blood pressure is averaged after excluding the first reading, while blood glucose is assessed using fasting blood glucose or HbA1c levels. Blood lipids are determined by measuring total cholesterol and high-density lipoprotein cholesterol levels. Self-administered questionnaires collect data on PA, smoking habits, sleep patterns, diabetes history, and medication use. CVH scores, based on the LE8 metrics, range from 0 to 100 and are determined by calculating the unweighted average of these individual metrics. These scores are categorized as follows: high (80–100), moderate (50–79), and low (0–49) [10]. The LE8 scoring method, as applied to adult NHANES data, is described in detail in Supplementary Table 1. Definition of MASLD FLI, calculated using triglycerides (TG), gamma-glutamyl transferase (GGT), body mass index (BMI), and waist circumference (WC), is a reliable tool for detecting hepatic steatosis, demonstrating high sensitivity and specificity [18, 19]. Individuals with an FLI score below 60 are considered unlikely to have hepatic steatosis, while those scoring 60 or above are likely to have steatotic liver disease (SLD) [20]. For diagnosing MASLD, individuals with viral hepatitis, autoimmune liver disease, hereditary liver disease, drug-induced liver disease, or excessive alcohol intake (≥ 30 g/day for men, ≥ 20 g/day for women) were excluded. MASLD diagnosis requires evidence of hepatic steatosis and at least one metabolic dysfunction criterion [1]. The detailed diagnostic process for MASLD can be found in Supplementary Fig. 1. Outcome ascertainment The primary outcomes of this study include all-cause mortality and CVD mortality. Data from the NHANES surveys conducted between 2005 and 2018 were used, with participant follow-up until December 31, 2019 [21]. All-cause mortality refers to deaths from any cause. CVD mortality encompasses deaths related to heart conditions, classified under ICD-10 codes I00-I09, I11, I13, and I20-I51. Participants characteristics and covariates Demographic characteristics of MASLD participants were collected from the NHANES database. These included age, sex, race/ethnicity, marital status, education level, family income, PA, alcohol consumption, CVD, blood pressure, and diabetes. Race/ethnicity was categorized as non-Hispanic white, non-Hispanic black, Mexican American, and other races. Marital status was divided into married or living with partners and living alone. Educational levels were classified as less than 9 years, 9 to 12 years, and more than 12 years of schooling. According to the U.S. government guidelines, family income was divided into three groups based on the poverty income ratio (PIR): low (PIR ≤ 1.3), middle (PIR > 1.3 to ≤ 3.5), and high (PIR > 3.5). PA was classified as sedentary (no leisure PA), moderate (at least 10 min of activity in the past 30 days causing light sweating or slight increases in breathing or heart rate), or vigorous (at least 10 min of activity in the past 30 days causing heavy sweating or large increases in breathing or heart rate). Alcohol consumption was categorized as follows: Never Drinkers are individuals who have consumed alcohol fewer than 12 drinks in their lifetime. Former Drinkers include those who consumed alcohol fewer than 12 drinks in the past year but have not consumed alcohol in the past year, or individuals with a lifetime consumption of 12 drinks or more but have not consumed alcohol in the past year. Mild Drinkers are defined as females who consume up to 1 drink per day and males up to 2 drinks per day. Moderate Drinkers are females who consume up to 2 drinks per day and males up to 3 drinks per day. Heavy Drinkers are females who consume 3 or more drinks per day and males who consume 4 or more drinks per day. History of CVD was self-reported as having been previously diagnosed with heart failure, coronary heart disease, angina, heart attack, or stroke. Hypertension was defined as a systolic blood pressure ≥ 140 mmHg, a diastolic blood pressure ≥ 90 mm Hg, a prior diagnosis by a physician, or the use of antihypertensive medication. Diabetes was defined as a physician diagnosis, an HbA1c level > 6.5%, fasting glucose ≥ 7 mmol/L, random blood glucose ≥ 11.1 mmol/L, a 2-hour oral glucose tolerance test with blood glucose ≥ 11.1 mmol/L, or the use of diabetes medications or insulin. Statistical analysis Baseline characteristics were described using LE8 scores; sample characteristics were reported as mean (SD) and median (IQR) for continuous variables and frequencies (percentages) for categorical variables. Differences among the three CVH groups based on LE8 scores (low, moderate, high) were assessed using one-way ANOVA for normally distributed continuous variables, Kruskal-Wallis test for non-normally distributed continuous variables, and chi-square test for categorical variables. Kaplan-Meier curves were used to compare survival across groups, with log-rank tests evaluating differences in cumulative mortality. Cox proportional hazards regression analysis was conducted to assess the association between LE8 and both all-cause and CVD mortality among individuals with MASLD.LE8 was included as both a continuous variable (with hazard ratios [HR] calculated for every 10-unit change) and a categorical variable (classified as low, intermediate, and high). Three statistical models were fitted: Model 1 adjusted for age, sex, race/ethnicity, education level, and marital status; Model 2 additionally adjusted for PIR, PA, and alcohol consumption; Model 3 further adjusted for CVD, diabetes, and hypertension, testing for linear trends using the median value of LE8 categories as a continuous variable. Restricted cubic spline (RCS) regression models explored dose-response relationships between LE8 levels and outcomes, with knots set at the 5th, 50th, and 95th percentiles of LE8 distribution. Likelihood ratio tests assessed nonlinearity. Subgroup analyses using stratified Cox regression models were conducted across various demographic and health status categories, including age groups (20–39,40–59, > 60years), sex (male, female), race (non-Hispanic white, non-Hispanic black, other), PIR (low and middle, high), alcohol consumption (never, former, mild, moderate, heavy), PA (sedentary, moderate, vigorous), and presence of CVD, diabetes, and hypertension (no, yes). Interaction terms were tested using likelihood ratio tests to explore potential outcome differences. To ensure the robustness of our findings, additional sensitivity analyses were conducted as follows: (1) associations between individual LE8 components and both all-cause and CVD mortality were examined; (2) to minimize potential reverse causality, participants who died within the first two years of follow-up (n = 505) were excluded, resulting in 5,411 participants for Cox regression analysis; (3) further, participants with self-reported CVD (including heart failure, coronary heart disease, angina, heart attack, or stroke; n = 836) were excluded, leaving 5,080 participants for Cox regression analysis. Statistical analyses were conducted using R version 4.2.2 (http://www.R-project.org, R Foundation) and Free Statistics software version 1.9.2. Statistical significance was set at a two-tailed P value < 0.05. This study adhered to Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines to ensure rigorous reporting of epidemiological observational studies. Results Characteristics of the participants The participants were classified into three groups according to their CVH scores based on LE8 scores: low, moderate, and high, as indicated in Table 1. From 2005 to 2018, 5,916 individuals diagnosed with MASLD were included in this study. During a median follow-up period of 7.58 years, there were 688 deaths, of which 184 were due to CVD. The average age of MASLD participants was 52.9 years. Of these, 1,135 were classified as having low CVH, 4,380 as moderate CVH, and 401 as high CVH. The high CVH group consisted mostly of younger individuals who were richer, had greater levels of education, and were largely non-Hispanic white (P < 0.001). In contrast, individuals with a history of CVD, hypertension, and diabetes were significantly less likely to achieve higher CVH scores (all P < 0.001). Table 1Baseline characteristics of the study population by three categories of total cardiovascular health (CVH) scoreCharacteristicsTotalLow CVH (0–49)Moderate CVH (50–79)High CVH (80–100)P value(n = 5916)(N = 1135)(N = 4380)(N = 401)Age52.9 ± 16.656.8 ± 14.552.4 ± 16.947.5 ± 16.5< 0.001Sex, n (%)< 0.001 Male3074 (52.0)535 (47.1)2306 (52.6)233 (58.1) Female2842 (48.0)600 (52.9)2074 (47.4)168 (41.9)Race/ethnicity a, n (%)< 0.001 Non-Hispanic White2744 (46.4)543 (47.8)2017 (46.1)184 (45.9) Non-Hispanic Black1188 (20.1)292 (25.7)867 (19.8)29 (7.2) Mexican American1011 (17.1)155 (13.7)761 (17.4)95 (23.7) Others b973 (16.4)145 (12.8)735 (16.8)93 (23.2)Education level (years), n (%)< 0.001 <9596 (10.1)149 (13.1)411 (9.4)36 (9) 9–122297 (38.8)556 (49)1644 (37.5)97 (24.2) >123023 (51.1)430 (37.9)2325 (53.1)268 (66.8)Marital status, n (%)< 0.001 Living alone c3710 (62.7)623 (54.9)2803 (64)284 (70.8) Married or living with a partner2206 (37.3)512 (45.1)1577 (36)117 (29.2)Family incomen, n(%)< 0.001 Low1835 (31.0)463 (40.8)1274 (29.1)98 (24.4) Medium2389 (40.4)479 (42.2)1763 (40.3)147 (36.7) High1692 (28.6)193 (17)1343 (30.7)156 (38.9)Physical activity< 0.001 Sedentary3239 (54.7)842 (74.2)2219 (50.7)178 (44.4) Moderate1423 (24.1)156 (13.7)1145 (26.1)122 (30.4) Vigorous1254 (21.2)137 (12.1)1016 (23.2)101 (25.2)Alcoholic Consumption, n (%)< 0.001 Never832 (14.1)130 (11.5)633 (14.5)69 (17.2)Former1274 (21.5)338 (29.8)893 (20.4)43 (10.7) Mild2120 (35.8)339 (29.9)1604 (36.6)177 (44.1) Moderate756 (12.8)141 (12.4)569 (13)46 (11.5) Heavy934 (15.8)187 (16.5)681 (15.5)66 (16.5)Waist circumference (cm)108.8 ± 13.4115.9 ± 14.7107.8 ± 12.6100.6 ± 8.9< 0.001Triglycerides (mg/dL)128.0 (92.0, 182.0)148.0 (105.0, 214.0)124.0 (90.0, 174.0)107.0 (83.0, 153.0)< 0.001Gamma-glutamyl-transferase (IU/L)23.0 (17.0, 34.0)26.0 (18.0, 40.0)23.0 (17.0, 33.0)22.0 (16.0, 32.0)< 0.001LE8 scores (out of 100 possible points) LE8 score61.1 ± 12.942.0 ± 6.264.0 ± 7.984.0 ± 3.5< 0.001Health Behaviors Score63.0 ± 19.040.4 ± 14.766.6 ± 15.187.7 ± 7.6< 0.001 Diet25.0 (0.0, 50.0)25.0 (0.0, 25.0)25.0 (0.0, 50.0)80.0 (50.0, 80.0)< 0.001 PA100.0 (0.0, 100.0)0.0 (0.0, 60.0)100.0 (20.0, 100.0)100.0 (100.0, 100.0)< 0.001 Nicotine exposure100.0 (55.0, 100.0)55.0 (0.0, 100.0)100.0 (75.0, 100.0)100.0 (100.0, 100.0)< 0.001 Sleep health100.0 (70.0, 100.0)70.0 (40.0, 100.0)100.0 (70.0, 100.0)100.0 (100.0, 100.0)< 0.001Health factors Score59.2 ± 16.043.7 ± 13.661.3 ± 13.680.4 ± 7.8< 0.001 Body mass index30.0 (15.0, 70.0)30.0 (15.0, 30.0)30.0 (15.0, 70.0)70.0 (30.0, 70.0)< 0.001 Blood lipids60.0 (40.0, 80.0)40.0 (20.0, 80.0)60.0 (40.0, 80.0)80.0 (60.0, 100.0)< 0.001 Blood glucose100.0 (60.0, 100.0)60.0 (30.0, 100.0)100.0 (60.0, 100.0)100.0 (100.0, 100.0)< 0.001 BP score55.0 (30.0, 100.0)30.0 (25.0, 75.0)75.0 (50.0, 100.0)100.0 (80.0, 100.0)< 0.001Cardiovascular disease d,n(%)< 0.001 No5080 (85.9)840 (74)3867 (88.3)373 (93) Yes836 (14.1)295 (26)513 (11.7)28 (7)Diabetes, n(%)< 0.001 No4306 (72.8)582 (51.3)3348 (76.4)376 (93.8) Yes1610 (27.2)553 (48.7)1032 (23.6)25 (6.2)Hypertension, n(%)< 0.001 No2782 (47.0)283 (24.9)2190 (50)309 (77.1) Yes3134 (53.0)852 (75.1)2190 (50)92 (22.9)CVH, cardiovascular health score; CVH scores range from 0 to 100 and are classified into low CVH (0–49), moderate CVH (50–79), and high CVH (80–100); aRace and ethnicity were self-reported. bNHANES does not provide a detailed list of all races and ethnicities; cIncluded widowed, divorced, or separated individuals; dIncludes congestive heart failure, coronary heart disease, angina, heart attack, and stroke Baseline characteristics of the study population by three categories of total cardiovascular health (CVH) score CVH, cardiovascular health score; CVH scores range from 0 to 100 and are classified into low CVH (0–49), moderate CVH (50–79), and high CVH (80–100); aRace and ethnicity were self-reported. bNHANES does not provide a detailed list of all races and ethnicities; cIncluded widowed, divorced, or separated individuals; dIncludes congestive heart failure, coronary heart disease, angina, heart attack, and stroke Association between LE8 with mortality outcomes of adults with MASLD Over a median follow-up of 7.6 years (interquartile range: 4.1–10.9 years), the impact of LE8 scores on all-cause and CVD mortality among MASLD participants was analyzed using Cox regression models (Table 2). After multivariable adjustment, higher LE8 scores were significantly associated with reduced all-cause and CVD mortality. Specifically, a 10-point increase in CVH level was linked to a 17% reduction in all-cause mortality (HR: 0.83; 95% CI: 0.78–0.89) and a 21% reduction in CVD mortality (HR: 0.79; 95% CI: 0.69–0.90). These associations persisted when CVH level was divided into three groups based on LE8 score(high CVH: 80–100 points; moderate CVH: 50–79 points; low CVH: 0–49 points). Compared to the low CVH group, the moderate CVH group had an HR of 0.67 (95% CI: 0.56–0.79) for all-cause mortality and 0.56 (95% CI: 0.41–0.78) for CVD mortality. The high CVH group had an HR of 0.53 (95% CI: 0.33–0.84) for all-cause mortality and 0.35 (95% CI: 0.12-1.0) for CVD mortality. A linear relationship was observed between LE8 scores and both all-cause and CVD mortality (nonlinearity P > 0.05; see supplementary Fig. 2). Participants with moderate and high CVH scores had significantly lower all-cause and CVD mortality rates compared to those with low CVH scores (Fig. 2). Table 2Association of Life’s essential 8 with all-cause, CVD mortality in participants with MASLDVariablesCase/participantsHR (95% CI)Crude ModelP-ValueModel 1P-ValueModel 2P-ValueModel 3P-ValueAll-cause mortalityPer 10 increase688/59160.75 (0.71 ~ 0.79)< 0.0010.78 (0.73 ~ 0.83)< 0.0010.82 (0.77 ~ 0.88)< 0.0010.83 (0.78 ~ 0.89)< 0.001Low212 /11351(Ref)1(Ref)1(Ref)1(Ref)Moderate454 /43800.52 (0.44 ~ 0.61)< 0.0010.56 (0.47 ~ 0.66)< 0.0010.64 (0.54 ~ 0.76)< 0.0010.67 (0.56 ~ 0.79)< 0.001High22 /4010.27 (0.18 ~ 0.42)< 0.0010.38 (0.24 ~ 0.6)< 0.0010.5 (0.32 ~ 0.78)0.0020.53 (0.33 ~ 0.84)0.007Trend.test< 0.001< 0.001< 0.001< 0.001Cardiovascular mortalityPer 10 increase184/59160.71 (0.64 ~ 0.79)< 0.0010.73 (0.65 ~ 0.82)< 0.0010.77 (0.68 ~ 0.87)< 0.0010.79 (0.69 ~ 0.9)0.001Low64 /11351(Ref)1(Ref)1(Ref)1(Ref)Moderate116/43800.44 (0.33 ~ 0.6)0.48 (0.35 ~ 0.65)< 0.0010.53 (0.38 ~ 0.73)< 0.0010.56 (0.41 ~ 0.78)0.001High4 /4010.17 (0.06 ~ 0.46)0.23 (0.08 ~ 0.65)0.0050.31 (0.11 ~ 0.87)0.0270.35 (0.12 ~ 1)0.05Trend.test< 0.001< 0.0010.001HR, hazard ratio; CI, confidence intervalModel 1. Adjusted for age, sex, race/ethnicity, marital statusModel 2. Adjusted for age, sex, race/ethnicity, marital status, educational level, PIR, Physical activity, drinking statusModel 3. Adjusted for age, sex, race/ethnicity, marital status, educational level, PIR, Physical activity, alcoholic consumption, CVD history, diabetes and hypertension Association of Life’s essential 8 with all-cause, CVD mortality in participants with MASLD HR, hazard ratio; CI, confidence interval Model 1. Adjusted for age, sex, race/ethnicity, marital status Model 2. Adjusted for age, sex, race/ethnicity, marital status, educational level, PIR, Physical activity, drinking status Model 3. Adjusted for age, sex, race/ethnicity, marital status, educational level, PIR, Physical activity, alcoholic consumption, CVD history, diabetes and hypertension Kaplan-Meier survival curve for all-cause and CVD mortality of MASLD participants Subgroup and sensitive analyses The outcomes of the subgroup analysis are illustrated in Fig. 3, covering subgroups categorized by age, sex, race/ethnicity, PIR, alcohol consumption, PA, and the presence of CVD, diabetes, and hypertension. LE8 scores were inversely related to all-cause and CVD mortality risks among MASLD participants. Interaction analysis for all-cause mortality revealed significant interactions between LE8 scores and both age and the presence of CVD (interaction P < 0.05). The relationship between LE8 scores and the risk of all-cause mortality was more pronounced in participants aged 40–59 years (hazard ratio per 10-point increase: 0.68; 95% CI: 0.59–0.78) and those without CVD (hazard ratio per 10-point increase: 0.75; 95% CI: 0.69–0.80). Interaction analysis for CVD mortality showed a significant correlation between LE8 scores and the presence of CVD (interaction P = 0.001). Forest plot of subgroup analysis for the association between LE8 score and mortality risk among participants with MASLD. Mortality risks encompass all-cause mortality, CVD mortality. Squares indicate hazard ratio, with horizontal lines indicating 95% CIs A series of sensitivity analyses were conducted to verify the robustness and consistency of the primary findings. First, in the independent analysis of each LE8 component, a 10-point increase in the health behaviors bcore corresponded to an 11% reduction in all-cause mortality risk, particularly for diet score, PA, and nicotine exposure, and a 11% reduction in CVD mortality risk, especially concerning sleep health. Additionally, a 10-point increase in the health factors score was linked to a 13% reduction in CVD mortality among MASLD participants, with blood glucose being the largest contributor (Table 3). Second, after excluding participants who died within the first two years of follow-up, the association between LE8 scores and both all-cause and CVD mortality remained consistent. Specifically, each 10-point increase in CVH score corresponded to a 17% reduction in all-cause mortality (HR: 0.83; 95% CI: 0.77–0.89) and a 22% reduction in CVD mortality (HR: 0.78; 95% CI: 0.68–0.90) (see supplementary Table 2). Third, after excluding participants with a history of CVD, each 10-point increase in CVH score was linked to a 19% reduction in all-cause mortality (HR: 0.81; 95% CI: 0.75–0.89) and a 17% reduction in CVD mortality (HR: 0.83; 95% CI: 0.76–0.90) (see supplementary Table 3). Table 3Association of Life’s essential 8 metrics with all-cause mortality, CVD mortality in the participants with MASLDCVH componentsAll-cause mortalityCardiovascular mortalityHR (95% CI)P valueHR (95% CI)P value Health Behaviors Score Age-, sex-, and race/ethnicity adjusted0.84 (0.81 ~ 0.88)< 0.0010.86 (0.8 ~ 0.93)< 0.001Fully adjusted0.89 (0.85 ~ 0.93)< 0.0010.89 (0.82 ~ 0.97)0.006 Diet score Age-, sex-, and race/ethnicity adjusted0.97 (0.94 ~ 0.99)0.010.98 (0.93 ~ 1.02)0.298Fully adjusted0.97 (0.95 ~ 1)0.0310.98 (0.93 ~ 1.03)0.372 Physical activity Age-, sex-, and race/ethnicity adjusted0.94 (0.93 ~ 0.96)< 0.0010.95 (0.92 ~ 0.99)0.005Fully adjusted0.96 (0.94 ~ 0.98)< 0.0010.97 (0.93 ~ 1.0)0.068 Nicotine exposure Age-, sex-, and race/ethnicity adjusted0.93 (0.91 ~ 0.95)< 0.0010.96 (0.91 ~ 1)0.069Fully adjusted0.95 (0.92 ~ 0.97)< 0.0010.98 (0.93 ~ 1.02)0.335 Sleep health Age-, sex-, and race/ethnicity adjusted0.96 (0.93 ~ 0.99)0.0050.92 (0.88 ~ 0.97)0.002Fully adjusted0.97 (0.95 ~ 1.0)0.0550.94 (0.89 ~ 0.99)0.015 Health factors Score Age-, sex-, and race/ethnicity adjusted0.91 (0.87 ~ 0.96)0.0010.82 (0.75 ~ 0.91)< 0.001Fully adjusted0.95 (0.9 ~ 1.01)0.1240.87 (0.77 ~ 0.97)0.014 Body mass index Age-, sex-, and race/ethnicity adjusted0.99 (0.96 ~ 1.01)0.3060.94 (0.89 ~ 1)0.034Fully adjusted1 (0.97 ~ 1.03)0.9650.96 (0.91 ~ 1.01)0.147 Blood lipids (non-HDL cholesterol) Age-, sex-, and race/ethnicity adjusted1 (0.97 ~ 1.03)0.8920.97 (0.92 ~ 1.02)0.258Fully adjusted0.99(0.96 ~ 1.02)0.4970.97 (0.92 ~ 1.02)0.186 Blood glucose Age-, sex-, and race/ethnicity adjusted0.93 (0.91 ~ 0.95)< 0.0010.9 (0.85 ~ 0.95)< 0.001Fully adjusted0.95 (0.92 ~ 0.99)0.0090.91 (0.85 ~ 0.98)0.011 Blood pressure Age-, sex-, and race/ethnicity adjusted0.99 (0.97 ~ 1.02)0.5750.99 (0.94 ~ 1.03)0.568Fully adjusted1 (0.97 ~ 1.02)0.7731 (0.95 ~ 1.06)0.95LE8 metrics were entered as a continuous variable per 10 points increaseFully adjusted: Adjusted for age, sex, race/ethnicity, marital status, educational level, PIR, Physical activity, alcoholic consumption, diabetes and hypertension Association of Life’s essential 8 metrics with all-cause mortality, CVD mortality in the participants with MASLD LE8 metrics were entered as a continuous variable per 10 points increase Fully adjusted: Adjusted for age, sex, race/ethnicity, marital status, educational level, PIR, Physical activity, alcoholic consumption, diabetes and hypertension Discussion This study, drawing on a nationally representative cohort of U.S. adults, demonstrates a significant inverse relationship between LE8 scores and both all-cause and CVD mortality risk among patients with MASLD. A 10-point increase in LE8 was linked to a 17% reduction in all-cause mortality and a 21% reduction in CVD mortality risk. These findings highlight the association between LE8 and CVD and all-cause mortality outcomes in MASLD, suggesting that improvements in CVH may have potential preventive effects in this population. In our subgroup analysis, a linear inverse relationship was observed between LE8 scores and both all-cause and cardiovascular disease (CVD) mortality, suggesting that higher LE8 scores may be associated with lower mortality risk. Notably, in the 20–39 age group, the association was weaker statistically due to the very low all-cause mortality rate (only 1.2%, or 17 cases). Further analysis revealed that in MASLD patients without a history of CVD, higher LE8 scores were associated with lower risks of both all-cause and CVD mortality. However, in individuals with existing CVD, the association between LE8 scores and mortality risk was relatively limited, likely due to their high-risk status and the complexity of disease progression. This finding is consistent with previous research showing that lower LE8 scores are associated with higher CVD prevalence and mortality, supporting our observation of differential LE8 effects based on CVD status [22, 23]. These results may suggest that in individuals with good cardiovascular health, LE8 scores, along with positive lifestyle factors such as dietary control, physical activity, and smoking cessation, contribute to maintaining lower disease risk. However, in patients with existing CVD, the relationship between LE8 scores and disease risk is likely more complex, influenced by multiple factors. Thus, caution should be exercised when interpreting and applying these findings, considering individual differences and disease status. The enhancement of LE8 over LS7, which includes sleep health and refined assessments of diet and physical activity (PA), better captures cardiovascular health (CVH) and predicts health outcomes. Our findings align with previous NHANES studies, including Sun et al. (2024) [23–25]. Sun et al. found that LE8 was associated not only with CVD prevalence in the NAFLD population but also with a non-linear relationship to CVD mortality. our study demonstrates a linear inverse relationship between LE8 and both all-cause and CVD mortality in the MASLD population. This distinction highlights the different patterns of association between LE8 and mortality outcomes in these two populations. This correlation has been validated in populations with chronic diseases such as chronic kidney disease (CKD) and cancer survivors [26–28], as well as in specific groups like Finnish men aged 42–60, hypertensive Americans aged ≥ 20, and young miners under 40 [29–31]. A meta-analysis of 193,126 adults found that each 1-point increase in ideal CVH metrics was associated with an 11% decrease in all-cause mortality and a 19% decrease in CVD mortality [32]. However, these studies used the simpler additive scoring method recommended by the AHA in 2010, which may oversimplify the relationship between CVH measures and mortality risk. The refined 0 to 100 scoring method in our study provides a more accurate assessment of CVH. While the mechanisms linking LE8 to mortality in MASLD are not fully understood, research shows significant associations between MASLD, metabolic syndrome, and healthy lifestyles—core elements of LE8’s health factors and behaviors [11, 33]. Our study highlights the importance of a healthy lifestyle in reducing mortality and improving overall health. Previous studies have established links between a healthy diet and lower risks of all-cause and CVD mortality [34–36]. High dietary quality is inversely related to mortality and aligns with AHA recommendations, as confirmed by our findings [35, 37]. Additionally, physical activity is crucial for reducing mortality rates in MASLD, as supported by our updated PA scoring in LE8 [38]. Non-smoking is associated with lower all-cause mortality risk, including from nicotine exposure and secondhand smoke [32]. Epidemiological studies indicate a U-shaped relationship between sleep duration and health outcomes, with both short and long sleepers at higher risk [39, 40]. Our study found that increased sleep scores significantly reduced CVD mortality risk. Furthermore, blood glucose, redefined in LE8 to include fasting glucose and HbA1c, emerged as a key factor for CVD-specific mortality, consistent with previous findings [23]. Previous studies have shown an inverse relationship between higher LE8 scores and the incidence of NAFLD, MAFLD, and liver fibrosis, with similar patterns in health behavior and factor scores [41–43]. However, Wang et al.‘s study had limitations, such as not accounting for participants’ baseline diseases [43]. This limitation was highlighted in a subsequent critique by Tang et al. [44]. Liang et al.‘s study adjusted for BMI and HDL, LE8 components, potentially introducing multicollinearity [42]. They found no significant association between LE8 scores and MAFLD incidence among participants with CVD or diabetes history. To date, no cohort studies have examined LE8 and mortality in MASLD populations. This study, based on a nationally representative sample of U.S. adults, excluded individuals with excessive alcohol consumption and other liver diseases, incorporated extensive demographic factors and chronic diseases related to mortality, enhancing the robustness and reliability of the findings. This study is based on a nationally representative sample of U.S. adults, with strict screening to exclude confounding factors and a comprehensive consideration of demographic characteristics and chronic diseases, ensuring the robustness and reliability of the conclusions. These findings may provide guidance for public policy and clinical practice regarding the role of LE8 metrics in the management of MASLD, indicating the need to improve cardiovascular health comprehensively, including promoting healthy diets, increasing physical activity, managing blood pressure and glucose levels, reducing smoking, and improving sleep quality. To our knowledge, this is the first cohort study to estimate the association between LE8 and mortality in a MASLD population. We found a dose-response relationship between overall CVH scores and mortality risk, with increased CVH scores significantly reducing mortality risk. Limitations of this study include the reliance on self-reported lifestyle factors, which may introduce recall bias, and potential confounding by both measured and unmeasured variables. Specifically, although we adjusted for major risk factors, there may still be residual confounding from unmeasured factors, such as genetic predispositions, social and environmental influences. These unmeasured factors could potentially impact both CVH and mortality outcomes, thus influencing our findings. Future studies incorporating these variables may help to clarify their impact on CVH and mortality in the MASLD population. Additionally, these findings are based on a U.S. population sample, and the generalizability to other populations with different lifestyle, genetic, or environmental backgrounds may be limited. Additionally, the relatively low incidence of CVD-specific mortality in our sample may reduce the statistical power of certain subgroup analyses. Future research in diverse populations and prospective studies examining individual LE8 components could provide further insights into the long-term impact of CVH improvement on health outcomes in MASLD. Conclusion In a nationwide population-based study, a strong association was found between higher LE8 scores and lower incidence and mortality risk of CVD in individuals diagnosed with MASLD, with a dose-response relationship observed for both all-cause and CVD mortality. These findings suggest the potential value of promoting cardiovascular health in this population. However, further research is needed to confirm these associations. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements The authors express their sincere thanks to those who developed and maintain the database, and to the clinical scientist team for their ongoing support and insightful guidance. Abbreviations Metabolic dysfunction-associated steatotic liver disease Cardiovascular disease Life’s essential 8 National health and nutrition examination survey Fatty liver index Triglycerides Fasting blood glucose Body mass index Waist circumference Gamma-Glutamyl transferase Physical activity Hemoglobin A1c Alcohol-related liver disease Life’s simple 7 Steatotic liver disease Type 2 diabetes mellitus Ischemic heart disease Poverty income ratio C-High-Density lipoprotein cholesterol Hazard ratio Confidence interval Restricted cubic spline Kaplan-Meier Chronic kidney disease Metabolic associated fatty liver disease Strengthening the reporting of observational studies in epidemiology Author contributions All authors contributed to the conception and design of the study. YYZ was responsible for data collection, analysis and drafted the initial manuscript. PPW was in charge of data collection, verification, and analysis, as well as proofreading the initial draft. FT was responsible for data collection. CFF and HK refined the study designs, performed additional analyses on the data, and revised the initial draft. All authors reviewed and commented on previous versions of the manuscript. They have all read and approved the final version of the manuscript for publication. Funding This study was funded by Scientific Research Project of Wuxi Health Committee (No. Q202366). Data availability The datasets supporting the conclusions of this study are publicly accessible. Detailed information on the repository names and accession numbers can be found at the National Center for Health Statistics, part of the Centers for Disease Control and Prevention website: http://www.cdc.gov/nchs/nhanes.htm (accessed on April 1, 2024). Declarations Ethical approval and informed consent The survey protocol for the NHANES was approved by CDC’s National Center for Health Statistics Institutional Research Ethics Review Board, with all participants giving informed consent. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Yingying Zhang and Pingping Wang contributed equally to this work and share first authorship. Contributor Information Hao Kang, Email: kanghao0908@163.com. Chengfeng Fu, Email: chengfengfu@stu.cqmu.edu.cn. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The datasets supporting the conclusions of this study are publicly accessible. Detailed information on the repository names and accession numbers can be found at the National Center for Health Statistics, part of the Centers for Disease Control and Prevention website: http://www.cdc.gov/nchs/nhanes.htm (accessed on April 1, 2024).